FFTY — Innovator IBD(R) 50 ETF
Data updated: 2026-03-27
FFTY — Innovator IBD(R) 50 ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Mid Cap Growth Equity · $85.88M AUM · 0.80% expense ratio · 21.2% 1-yr return. From SEC regulatory filings.
FFTY Fund Overview
FFTY — Innovator IBD(R) 50 ETF is a US ETF managed by Innovator ETFs Trust, categorised as United States Mid Cap Growth Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Innovator ETFs Trust
- Category: United States Mid Cap Growth Equity
- Assets under management: $85.88M
- 1-year return: 21.2%
- Ticker: FFTY
- SEC CIK: 0001415726
- SEC series ID: S000047761
- Share class ID: C000150102
FFTY Holdings
Top 10 holdings of Innovator IBD(R) 50 ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Mount Vernon Liquid Assets Portfolio, LLC | 19.19% |
| Mirum Pharmaceuticals Inc | 4.06% |
| Micron Technology Inc | 3.91% |
| AnaptysBio Inc | 3.72% |
| Comfort Systems USA Inc | 3.65% |
| FTAI Aviation Ltd | 3.48% |
| IAMGOLD Corp | 3.46% |
| PACS Group Inc | 3.43% |
| Rocket Lab Corp | 3.34% |
| Celestica Inc | 3.33% |
FFTY Portfolio Allocation
Asset-class allocation of Innovator IBD(R) 50 ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 100.0% |
| Cash & Equivalents | 19.4% |
FFTY Performance
Total returns for FFTY (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 2.6% |
| 1 year | 21.2% |
| 3 years (annualised) | 16.6% |
| 5 years (annualised) | -2.6% |
FFTY Risk Information
Risk metrics for FFTY, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 23.6%
FFTY Costs and Fees
FFTY costs about $80 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.80%
- Gross expense ratio: 1.03%
- Portfolio turnover: 1209%
- Brokerage commissions: 47.44 bps of average net assets (SEC N-CEN)
FFTY Cashflows
Over the 12 months to 2026-01, Innovator IBD(R) 50 ETF had net inflows of $3.02M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-01 | $5.59M |
| 2025-12 | −$10.54M |
| 2025-11 | −$8.05M |
| 2025-10 | $5.92M |
| 2025-09 | $20.36M |
| 2025-08 | −$11.65M |
FFTY Debt Constituents
No individual debt constituents are reported in Innovator IBD(R) 50 ETF's latest SEC N-PORT filing.
FFTY Prospectus and SEC Filings
Official Innovator IBD(R) 50 ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Mid Cap Growth Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.